January 30, 2012
by admin
0 comments
The sale of Avila to Celgene may mark the pinnacle of the market for kinase inhibitors in cancer. Where might early stage drug discoverers in cancer start looking now if they want to create successes like Avila in five to … Continue reading
January 23, 2012
by admin
1 Comment
Why Merck’s CETP Inhibitor programme is such a huge gamble – and why DrugBaron fears the odds are stacked against them. Few programmes in the pharmaceutical industry were born with such optimism as the search for CETP inhibitors. Decades of … Continue reading
January 3, 2012
by admin
0 comments
DrugBaron wishes his readers a Happy New Year. But how happy 2012 will really be, at least from a biotech perspective, must be open to doubt. If the health of the drug industry depends on the uptake of its products, … Continue reading